Flow-Mediated Dilation, a Marker of Endothelial Cell Dysfunction, in Patients with Pulmonary Hypertension

Ahmad Mirdamadi1, Mohammad Shirzad2, Raana Abrishamkar2

  • 1Department of Cardiology, Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran.

Tanaffos
|October 21, 2022
PubMed

Insights

Flow-mediated dilation (FMD) indicates endothelial cell dysfunction in pulmonary hypertension (PH). FMD and 6-minute walk tests are objective prognostic markers for PH, while pro-BNP aids in diagnosing right ventricular dysfunction.

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Medicine
  • Vascular Biology

Background:

  • Endothelial cell dysfunction (ECD) is linked to cardiovascular diseases.
  • The role of ECD in pulmonary hypertension (PH) pathogenesis is not well understood.
  • Flow-mediated dilation (FMD) is a key indicator of ECD.

Purpose of the Study:

  • To investigate the relationship between FMD and PH.
  • To assess FMD as a potential marker in PH patients.

Main Methods:

  • Cross-sectional study of 40 PH patients.
  • Brachial artery FMD measurement.
  • Evaluation of echocardiography, 6-minute walk test (6MWT), and pro-brain natriuretic peptide (pro-BNP).

Main Results:

  • Significant direct correlation between left ventricular ejection fraction and FMD.
  • Significant inverse relationship between pro-BNP and FMD.
  • Significant direct correlation between right ventricular (RV) function and FMD.
  • RV dilation correlated with pro-BNP.
  • Inverse relationship between pro-BNP and 6MWT.

Conclusions:

  • Endothelial function, assessed by FMD, is relevant in PH.
  • FMD and 6MWT serve as objective prognostic markers in PH.
  • Pro-BNP is a noninvasive indicator for diagnosing RV systolic dysfunction.
Abstract